The SELECT trial, published in 2023, demonstrated that semaglutide 2.4 mg (Wegovy) reduced the risk of major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease but without diabetes
Recent studies have leveraged the abnormal vascular structure of tumors, and the size advantage of nanoparticles (typically less than 200 nm), to achieve selective accumulation at prostate lesions via enhanced EPR
Medical and Lifestyle Factors That Increase Risk Obesity is a major risk factor, as a higher body weight is associated with increased cholesterol in the bile
Yes, metformin and semaglutide (Ozempic) are generally safe to use together because they work through different metabolic mechanisms and have no significant drug-drug interactions
MRM transitions of modified peptides were integrated using Sciex MultiQuant 2.1
10.1021/acs.jmedchem.5b00726 62